Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Brendan P. Eckelman, Sant P. Chawla et al.|Clinical Cancer Research|2023Cited by 40
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, Débora S. Bruno et al.|Journal of Thoracic Oncology|2023Cited by 38